The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome-A Systematic Review.

ABSTRACT: Irritable bowel syndrome (IBS) is a common gastrointestinal tract disorder, affecting 10-20% of adults worldwide. Mebeverine is an antispasmodic agent indicated for the symptomatic treatment of abdominal pain caused by intestinal smooth muscle spasms and intestinal functional disorders in the course of IBS. The aim of this article was to perform a systematic literature review and update previous overviews of the efficacy and safety of mebeverine treatment in IBS. Major electronic medical databases, PubMed, EMBASE and Cochrane, were systematically searched from January 1965 to January 2021. Twenty-two studies met our inclusion criteria, including 19 randomised trials, two observational retrospective studies, and one non-randomised, single-blinded study. Six studies reported a significant de

SUBMITTER: Daniluk J 

PROVIDER: S-EPMC8879004 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature